Research study on the treatment patterns of gastrointestinal stromal tumor (GIST) using the claims database

UMIN ID: UMIN000054074

Registered date:05/04/2024

Basic Information

• Recruitment status: Complete: follow-up continuing
• Health condition(s) or Problem(s) studied: Gastrointestinal stromal tumor (GIST)
• Date of first enrollment: 2023/11/24
• Target sample size: 2500
• Countries of recruitment: Japan
• Study type: Observational

Outcome(s)

• Primary Outcome: To explore the treatment patterns of GIST drug
• Secondary Outcome: Time to treatment failure by GIST drug Overall survival by GIST drug Overall survival by the number of GIST drugs used Exploration of treatment patterns and overall survival after regorafenib Proportion of adverse events by GIST drug Proportion of patients who experienced GIST-related surgeries and overall survival with or without GIST-related surgery after starting GIST treatment Distribution of the number of rechallenges

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: Patients with a record of antitumor drug prescription other than GIST drugs, at least 60 days before the first prescription of GIST drugs Patients who have a history of radical surgery for GIST, who have received Imatinib as the first prescription, and who have not received any GIST drugs after the completion of Imatinib treatment (adjuvant therapy period)

Related Information

• Primary Sponsor: TAIHO PHARMACEUTICAL CO., LTD.
• Source(s) of Monetary Support: None